RxDoctor Payments Data

Svetlana Luvish, DPM

Foot Surgery · Brooklyn, NYNPI 1699742619

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.9% of the total across 74 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 20.6% — the pattern of someone who eats at a lot of different presentations.

$3,685in general payments, 2019–2025

Across 74 payments — averaging $49.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Organogenesis Inc.$758
  • Sunovion Pharmaceuticals Inc.$419
  • Ortho Dermatologics, A Division Of Bausch Health US, LLC$385
  • Advanced Oxygen Therapy Inc.$352
  • Smith+Nephew$298
  • Abbott$276
  • plus $1K from 11 others

What the payments were for

  • Food & beverage$3,680100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,685 in reported general payments places this provider in the 85th percentile of 294 foot surgery providers in New York.

See all foot surgery providers in New York

Medicare billing

Part B allowed, 2024
$338,265
Medicare patients
788
Services billed
5,288

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JubliaEfinaconazole191$258,300
Tavaborole26$26,181
Clotrimazole329$11,447
Diclofenac Sodium107$8,833
Ciclopirox253$8,090
Ammonium Lactate648$8,065
SantylCollagenase Clostridium Hist.16$6,419
Ketoconazole152$4,856
Doxepin Hcl13$2,977
CiclopiroxCiclopirox Olamine114$2,370
Econazole Nitrate30$1,330
Clobetasol Propionate11$1,264
Celecoxib17$1,059
Betamethasone Dipropionate31$1,007
Halobetasol Propionate11$344

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia$385$258,300191 claims
Smith+NephewSantyl$298$6,41916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 294 foot surgery providers in New York.

Other foot surgery in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →